So Far So Good: With Phase III Data, Keryx Says Zerenex Will Stand Out In ESRD Crowd
Company set to price drug up to 20% below Genzyme's market leading Renvela/Renagel franchise, and ponders impact of new Medicare bundling regime for phosphate binders used in end-stage renal disease.